JAK Inhibitors in Dermatology: The Promise of a New Drug Class

JAK inhibitors, such as tofacitinib, ruxolitinib, and baricitinib, showed significant promise in treating various inflammatory skin conditions, including alopecia areata, atopic dermatitis, psoriasis, and vitiligo. These drugs demonstrated efficacy in promoting hair regrowth, reducing symptoms, and achieving substantial clinical improvements in patients who had not responded to other treatments. Safety concerns included risks of infection, cytopenias, and potential malignancy, but these were generally manageable. The versatility of JAK inhibitors, with both oral and topical administration options, suggested a promising future for this drug class in dermatology, with ongoing clinical trials further exploring their potential.